For a patient with a spinal cord injury, the goal of rehabilitation is not just to move a limb, but to rewire the brain. In a 2025 systematic review published in the Global Spine Journal, researchers identified only one device that demonstrated an ability to induce neuroplasticity: the Hybrid Assistive Limb, or HAL, from Japan's Cyberdyne Inc. [Cyberdyne.eu, Cyberdyne.com, 2026]. This finding frames the two-decade ambition of founder Yoshiyuki Sankai.
Cyberdyne is an unusual entity in the healthtech landscape. Founded in 2004 and publicly traded on the Tokyo Stock Exchange since 2014, it is not a venture-backed startup chasing hypergrowth [Cyberdyne.jp, 2024]. It is a professor's life's work, commercialized. Sankai, a professor at the University of Tsukuba, began mapping the neurons governing leg movement in the early 1990s, inspired in childhood by anime cyborgs [Forbes, 2006]. His company's mission is "Cybernics," a field merging human, robot, and information systems. For the last twenty years, that has meant building and leasing robotic exoskeletons, primarily in Japan. Now, with fresh FDA clearance in hand and a landmark peer-reviewed claim, Cyberdyne's patient-focused bet is entering a new, evidence-driven phase.
The Clinical Wedge: Evidence Over Hype
In the crowded field of medical exoskeletons, where competitors like ReWalk and Ekso Bionics also hold FDA clearances, differentiation is critical. Cyberdyne's wedge is not raw strength or speed, but a specific physiological claim: that its system can facilitate neurorecovery. The HAL suit uses bio-electric sensors placed on the skin to detect faint neuromuscular signals from the wearer's brain. It then assists movement in concert with the user's own intent. The theory is that this closed-loop feedback can help retrain damaged neural pathways [Cyberdyne.jp, 2024].
Cyberdyne first submitted a De Novo application to the U.S. Food and Drug Administration in November 2014 [Cyberdyne.jp, 2026]. It received FDA marketing clearance as a Class II medical device for use in rehabilitation centers for patients with spinal cord injuries and stroke in December 2017 [Exoskeleton Report, 2017]. A broader clearance followed in May 2024 [Cyberdyne.jp, 2024].
A Business Model Built for a Super-Aged Society
While the science aims for neuroplasticity, the business model is built for accessibility and sustainability in Cyberdyne's home market. Japan faces one of the world's most acute aging populations, creating immense pressure on welfare and rehabilitation systems. Cyberdyne's answer is a rental model, not a direct sale. Institutions, hospitals, nursing homes, and rehabilitation centers, lease HAL units for a reported monthly fee of $2,000 [Wikipedia (Hybrid Assistive Limb), 2026]. By early 2013, the company had leased approximately 330 units to 150 institutions across Japan [Grokipedia, 2026].
This model has yielded modest but stable financials for the public company. Reported revenue was $28.8 million in 2024, with essentially flat growth into 2025 at $30.3 million [BCC Research, 2024] [GlobalData, 2026]. With a market capitalization around $212 million, Cyberdyne operates more like a niche medical device company than a high-flying tech stock [GlobalData, 2026].
| Metric | Figure |
|---|---|
| Revenue | $30.3M |
| Market Cap | $212.1M |
| HAL Units Leased (Japan) | 330 |
| Monthly Rental Fee | $2,000 |
| FDA Clearance (Medical HAL) | Obtained |
Where the Ambition Meets Friction
For all its scientific promise and domestic grounding, Cyberdyne's path to broader impact faces clear headwinds. The company's global footprint remains limited. The HAL suit is available for institutional rental only in Japan, and while a smaller "for Child" version is marketed globally, significant commercial expansion into markets like the U.S. or Europe is not yet evident in the public record [Wikipedia (Hybrid Assistive Limb), 2026] [MedicalExpo, 2026]. The company's recent appointment of Shinji Honda as Executive Director and COO in late 2023 may signal a renewed focus on operational execution for this next phase [Cyberdyne.jp, 2026].
The Next Phase: Evidence in Motion
The next twelve months for Cyberdyne will be less about a splashy new product launch and more about the hard work of translating its clinical evidence into broader adoption. Key milestones to watch will be any formal partnerships with major rehabilitation hospital networks outside Japan, which would validate its international expansion strategy. Furthermore, subsequent clinical studies building on the 2025 neuroplasticity review will be crucial for convincing skeptical physiatrists and, ultimately, insurance payers.